Comparison of opioid doctor shopping for tapentadol and oxycodone: a cohort study.

UNLABELLED Obtaining opioids from multiple prescribers, known as doctor shopping, is 1 example of opioid abuse and diversion. The dual mechanism of action of tapentadol could make tapentadol less likely to be abused than other opioids. The aim of this retrospective cohort study was to compare the risk of shopping behavior between tapentadol immediate release (IR) and oxycodone IR. Subjects exposed to tapentadol or oxycodone with no recent opioid use were included and followed for 1 year. The primary outcome was the proportion of subjects who developed shopping behavior defined as subjects who had opioid prescriptions written by >1 prescriber with ≥1 day of overlap filled at ≥3 pharmacies. The opioids involved in the shopping episodes were assessed. A total of 112,821 subjects were exposed to oxycodone and 42,940 to tapentadol. Shopping behavior was seen in .8% of the subjects in the oxycodone group and in .2% of the subjects in the tapentadol group, for an adjusted odds ratio of 3.5 (95% confidence interval, 2.8 to 4.4). In the oxycodone group, 28.0% of the shopping events involved exclusively oxycodone, whereas in the tapentadol group, .6% of the shopping events involved exclusively tapentadol. Results suggest that the risk of shopping behavior is substantially lower with tapentadol than with oxycodone. PERSPECTIVE The risk of opioid doctor shopping, ie, obtaining opioid prescriptions from multiple prescribers, is lower with tapentadol than with oxycodone.

[1]  N. Dasgupta,et al.  OPIOIDS, SUBSTANCE ABUSE & ADDICTIONS SECTION Original Research Article Post-marketing Surveillance of Methadone and Buprenorphine in the United States , 2010 .

[2]  T. Neylan,et al.  Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. , 2012, JAMA.

[3]  N. Volkow,et al.  Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. , 2011, JAMA.

[4]  Matt Schiller,et al.  Analytic models to identify patients at risk for prescription opioid abuse. , 2009, The American journal of managed care.

[5]  B. Kuehn.  Opioid Prescriptions Soar , 2007 .

[6]  Wing Chow,et al.  A Large Cohort Study from a Medication Dispensing Database in the US , 2012 .

[7]  C. Rauschkolb,et al.  Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride , 2011, Advances in therapy.

[8]  Nora D Volkow,et al.  Major increases in opioid analgesic abuse in the United States: concerns and strategies. , 2006, Drug and alcohol dependence.

[9]  M Soledad Cepeda,et al.  Assessing Opioid Shopping Behaviour , 2012, Drug Safety.

[10]  K. Schiene,et al.  (–)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol Hydrochloride (Tapentadol HCl): a Novel μ-Opioid Receptor Agonist/Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic Properties , 2007, Journal of Pharmacology and Experimental Therapeutics.

[11]  H. Kress.  Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally‐acting analgesics on the horizon? , 2010, European journal of pain.

[12]  Meelee Kim,et al.  Usefulness of prescription monitoring programs for surveillance—analysis of Schedule II opioid prescription data in Massachusetts, 1996–2006 , 2010, Pharmacoepidemiology and drug safety.

[13]  R. Dart,et al.  Street Prices of Prescription Opioids Diverted to the Illicit Market: Data from a National Surveillance Program , 2013 .

[14]  L. Hourani,et al.  Results from the 2008 National Survey on Drug Use and Health: National Findings , 2007 .

[15]  K. Wells,et al.  Association between mental health disorders, problem drug use, and regular prescription opioid use. , 2006, Archives of internal medicine.

[16]  J David Haddox,et al.  Identifying controlled substance patterns of utilization requiring evaluation using administrative claims data. , 2004, The American journal of managed care.

[17]  Grant T. Baldwin,et al.  CDC grand rounds , 2012 .

[18]  J. Berlin,et al.  Characteristics of prescribers whose patients shop for opioids: results from a cohort study. , 2012, Journal of opioid management.

[19]  Christopher M. Jones,et al.  CDC Grand Rounds: Prescription Drug Overdoes - A U.S. Epidemic , 2012 .

[20]  M Soledad Cepeda,et al.  Opioid Shopping Behavior: How Often, How Soon, Which Drugs, and What Payment Method , 2013, Journal of clinical pharmacology.

[21]  D. Spence.  The painful truth: deaths and misuse of prescribed drugs , 2011, BMJ : British Medical Journal.

[22]  W. Bilker,et al.  Factors influencing the optimal control-to-case ratio in matched case-control studies. , 1999, American journal of epidemiology.

[23]  K. Befort,et al.  Reward processing by the opioid system in the brain. , 2009, Physiological reviews.

[24]  Sandro Galea,et al.  The social epidemiology of substance use. , 2004, Epidemiologic reviews.

[25]  B. Kuehn.  Opioid prescriptions soar: increase in legitimate use as well as abuse. , 2007, JAMA.

[26]  P. Buckley,et al.  Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: The TROUP Study , 2012 .

[27]  K. Brady,et al.  Gender and prescription opioids: findings from the National Survey on Drug Use and Health. , 2010, Addictive behaviors.

[28]  D. Gagnon,et al.  Characterizations of long-term oxycodone/acetaminophen prescriptions in veteran patients. , 2004, Archives of internal medicine.

[29]  Z. Pan,et al.  Synaptic Mechanism for Functional Synergism between δ- and μ-Opioid Receptors , 2010, The Journal of Neuroscience.

[30]  S. Butler,et al.  Abuse risks and routes of administration of different prescription opioid compounds and formulations , 2011, Harm reduction journal.

[31]  L. Simon.  RELIEVING PAIN IN AMERICA: A BLUEPRINT FOR TRANSFORMING PREVENTION, CARE, EDUCATION, AND RESEARCH , 2012 .